First GLP-1/GIP Receptor Agonist OK'd for Type 2 Diabetes

(MedPage Today) -- The FDA approved first-in-class tirzepatide (Mounjaro) for patients with type 2 diabetes, the agency announced on Friday.
Tirzepatide, a glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide (GLP-1/GIP) agonist...